Swiss Medica Receives FDA Certificates of Free Sale for O24 that Allow for International Distribution
websol...@hotmail.com
for International Distribution
TORONTO, ONTARIO--(CCNMatthews - June 12, 2006) - Swiss Medica, Inc.
(OTCBB:SWME) announced today that the company has received Certificates
of Free Sale from the US Food and Drug Administration ("FDA") for its
patented O24 Pain Neutralizer and O24 Fibromyalgia products.
This issuance of these certificates by the FDA confirms that Swiss
Medica's O24 Pain Neutralizer and O24TM Fibromyalgia products meet all
the standards necessary for international export. Certificates of Free
Sale confirm to foreign governments that the products meet or exceed
all the standards necessary for them to be marketed in the United
States, and meet specific US manufacturing regulations such as cGMP
(current Good Manufacturing Practice). Many countries required these
certificates prior to allowing importation of U.S. manufactured
healthcare products like O24.
O24 Pain Neutralizer was launched nationally in the United States by
Swiss Medica in 2005 and is available in the pain relief section of
leading pharmacies throughout North America. The topical pain reliever
and anti-inflammatory is a patented, medically/clinically tested, all
natural product formulated with seven essential oils and no chemical
binders. It has being used by and recommended by leading healthcare
professionals including Medical Doctors and Doctors of Osteopathy. In
addition, athletes from many sports including football, hockey, boxing
and skiing like O24 for its quick pain relief and non-doping
ingredients.
O24 Fibromyalgia was launched in late 2005 and is the first patented,
clinically tested and non-prescription product specifically for
patients to fight the intense, debilitating pain caused by
Fibromyalgia. The product was awarded the first ever Seal of Approval
from the U.S. National Fibromyalgia Association (NFA).
O24 has been medically and clinically tested and details of those
trials are available at http://024zone.com/Clinicals.html.
Swiss Medica President and Chief Operating Officer Grant Johnson stated
"The FDA's issuance of these certificates is coming at a perfect time.
International interest in our products is growing quickly because of
the science behind our products and the extraordinary efficacy of O24
for most people with pain."
About Swiss Medica, Inc.
Swiss Medica is a specialty pharmaceutical company focused on
commercializing over-the-counter clinically-tested, patented
all-natural products that relieve chronic ailments. Swiss Medica builds
its brands through innovative and focused distribution and marketing
strategies. Swiss Medica's mission is to be a world leader in the
commercialization of over-the-counter, safe and effective chronic
ailment treatments. Please visit our websites at www.swissmedica.com,
www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24 Essential Oil Pain
Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution
has been used and recommended for its fast-acting and long-lasting
benefits by healthcare professionals and athletes in the United States,
Canada and in Europe. O24 is widely available over-the-counter
throughout the United States and Canada in leading pharmacies and other
retailers. Customers can also visit www.O24zone.com, for ordering
details and store locators for the nearest pharmacy.
Swiss Medica has recently launching the patented O24 Fibromyalgia pain
reliever (US Patent #6,444,238B1) over-the-counter in North American
retailers. The National Fibromyalgia Association (NFA) recently awarded
O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million
Americans suffer from the long-term pain associated with Fibromyalgia.
In a randomized double blind clinical trial conducted in 2005, 88 per
cent of the patients who used O24 Fibromyalgia reported mild to
markedly better improvement, versus only 7 per cent who used the
placebo. Customers can also visit www.O24zone.com, for ordering details
and store locators for the nearest retailer.
Swiss Medica also distributes PMS Escape® which holds US Patent #'s
5760014 and 5612320. PMS Escape® is a specially formulated group of
carbohydrates, vitamins and minerals, clinically proven to reduce
changes in mood and appetite that women experience during the
premenstrual period. Customers can also visit: www.pmsescape.com for
additional information and ordering details.
Forward-looking statements in this news release are made pursuant to
the "Safe Harbor" provisions of the United States Private Securities
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties, including,
without limitation, risks relating to acceptance of Swiss Medica's
products in Canada, the United States and other countries, risks
related to international sales and purchases and potential foreign
currency exchange fluctuations, acceptance of Swiss Medica's products,
increased levels of competition, dependence on intellectual property
rights and other risks detailed from time to time in Swiss Medica's
periodic reports filed with the United States Securities and Exchange
Commission and other regulatory authorities.
CONTACT INFORMATION
Emerging Markets Consulting, LLC
James Painter
(321) 206-6682
jamesp...@emergingmarketsllc.com
www.emergingmarketsllc.com
or
Swiss Medica, Inc.
Investor Relations Contact
David Jones
(866) 485-4243
djo...@swissmedica.com
or
Fusion Communications
Media Contact
Dean Mailey
(604) 218-6767
de...@fusioncom.ca